New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
08:11 EDTLGND, TGTXTG completes global license agreement with Ligand for IRAK4
TG Therapeutics (TGTX), announced an agreement with Ligand Pharmaceuticals (LGND) to license exclusive global rights to develop and commercialize Ligand's IRAK4 inhibitor research program. The IRAK4 program is currently in pre-clinical development. Under the terms of the agreement, Ligand will receive an up-front licensing fee of 125k unregistered shares of TG Therapeutics' common stock. In addition, TG will make development and sales-based milestone payments and will pay a tiered, mid-to-high single digit royalty on net sales.
News For TGTX;LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
10:28 EDTLGNDLigand sees 2015 revenue $81M-$83M, consensus $91.87M
Three estimates make up consensus. Guidance issued in analyst day presentation slides.
10:27 EDTLGNDLigand sees 2017 EPS above $4.65, revenue above $146M
Subscribe for More Information
10:27 EDTLGNDLigand sees 2016 EPS above $3.20, revenue above $107M
Subscribe for More Information
10:25 EDTLGNDLigand guides 2015 EPS $2.14-$2.18, consensus $2.42
Subscribe for More Information
November 14, 2014
17:21 EDTLGNDLigand to host analyst day
Analyst Day to be held in New York on November 18 at 10 am. Webcast Link
November 12, 2014
09:16 EDTLGNDLigand reports GlaxoSmithKline EU regulatory submission for Revolade
Subscribe for More Information
November 11, 2014
13:14 EDTTGTXTG Therapeutics Phase 3 trial highly likely to succed, says Brean Capital
Subscribe for More Information
November 10, 2014
16:26 EDTTGTXTG Therapeutics reports Q3 EPS with items (51c), consensus (32c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use